These findings suggest that mTOR signaling during treatment might be activated by constitutive amino acid transporter LAT1 overexpression, regulating amino acid uptake and in response to oxaliplatin, at least in CRC patients. The gene discussed is SLC38A7; the disease is colorectal carcinoma.